- Patent Title: Targeted therapeutics based on engineered proteins that bind EGFR
-
Application No.: US15886118Application Date: 2018-02-01
-
Publication No.: US10781247B2Publication Date: 2020-09-22
- Inventor: Ray Camphausen , Brent Morse , Stuart Emanuel , David Fabrizio
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee Address: US NJ Princeton
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.; Christopher L. Frank
- Main IPC: C07K14/78
- IPC: C07K14/78 ; C07K16/28 ; C07K14/76 ; C07K14/765 ; C07K14/79 ; C07K19/00 ; A61K38/00
Abstract:
The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
Public/Granted literature
- US20180244755A1 TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR Public/Granted day:2018-08-30
Information query
